Skip to main content

Table 1 Characteristics of PML patients

From: JCPyV NCCR analysis in PML patients with different risk factors: exploring common rearrangements as essential changes for neuropathogenesis

  HIV Risk factor CSF composition CD4/CD8 ratio (blood) CSF JCPyV-DNA IU/mL NCCR organization
Case 1 negative natalizumab glucose: 54 mg/dl proteins: 569 mg/L cell count: 5 cells/μl 0.45 1.62 × 106 A–B*–C–E–F
Case 2 negative dimethyl fumarate glucose: 56 mg/dl proteins: 35 mg/L cell count: 2 cells/μl 5.36 4.9 × 105 A–B–C–(D)–E–F
Case 3 positive HIV infection glucose: 76 mg/dl proteins: 413 mg/L cell count: 2 cells/μl 0.10 8.97 × 105 A-B-(C)-(E)-(F)-(B)-(C)-(E)-F*
Case 4 positive HIV infection glucose: 43 mg/dl proteins: 46 mg/L cell count: 2 cells/μl 0.11 2.34 × 106 A–C*–E*–F*
  1. Letter in brackets indicates the presence of a rearranged block. Asterisk (*) indicates a single nucleotide polymorphism. CSF cerebrospinal fluid, JCPyV JC polyomavirus, NCCR non-coding control region